Abstract 2191P
Background
Based on the positive results of the CheckMate-743 trial, first-line (1L) treatment of MPM with ipilimumab in combination with nivolumab (ipi/nivo) has become a standard 1L treatment in patients (pts) with non-epithelioid MPM and epithelioid MPM. Pts who received 1L platinum-pemetrexed are often considered for further-line treatment with ipi/nivo based on the MAPS2 trial results. Here we report on real-world survival outcomes and toxicity with ipi/nivo for treatment of MPM in Switzerland.
Methods
This was a retrospective multicenter analysis in 12 Swiss centers including all pts treated with ipi/nivo for MPM; data cut-off was on May 1, 2023. Pts’ characteristics including age, sex, histology, PD-L1, ECOG and previous/subsequent treatments were collected. Efficacy and safety outcomes were assessed by local investigators.
Results
Of 109 patients with MPM (75% epithelioid, 9% biphasic, 16% sarcomatoid) treated with ipi/nivo (start of treatment November 2017-March 2023) median age was 72 years, 91% were males, and 83% had ECOG 0-1 at start of ipi/nivo. Ipi/nivo was given as 1L treatment in 43%, as 2L or further line in 57% of pts. 2 year-completion rate of ipi/nivo was 0%; treatment is ongoing in 16 pts (15%). Median follow-up from start of ipi/nivo was 16.6 months (mo). Efficacy outcomes for ipi/nivo are shown in the table. Highest-grade adverse events (AE) were as follows: 14% G1, 22% G2, 21% G3, 2% G4 and 3% G5 (1 colitis, 2 pneumonitis). Treatment discontinuation rate due to toxicity was 19%.
Table: 2191P
Outcomes
total (n=109) | 1L (n=47) | Further line (n=62) | |
ORR (95% CI) | 17 % (11-26%) | 21% (11-36%) | 15% (7-26%) |
DCR (95% CI) | 46% (36-56%) | 62% (46-76%) | 34% (22-47%) |
mPFS (95% CI), mo | 3.4 (2.9-5.0) | 6.5 (3.5-10.6) | 2.8 (2.3-3.4) |
mOS (95% CI), mo | 10.6 (6.1-12.2) | 12.6 (6.5-16.5) | 6.9 (4.5-11.6) |
OS at 6 mo (95% CI) | 62% (52-71%) | 70% (53-81%) | 57% (44-68%) |
OS at 12 mo (95% CI) | 42% (32-52%) | 55% (38-69%) | 34% (22-46%) |
Conclusions
In this real-world cohort of MPM pts treated with ipi/nivo efficacy outcomes were inferior to those reported in the CM743 and MAPS2 trials, while safety outcomes were similar. Subgroup analyses by histology, PD-L1 expression, age and ECOG will be presented at the meeting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S. Schmid: Financial Interests, Institutional, Advisory Board: AstraZeneca, MSD, BMS, Merck; Financial Interests, Institutional, Funding: Janssen, BMS, AstraZeneca; Financial Interests, Personal, Other, Congress travel support: Takeda, MSD, Amgen; Financial Interests, Institutional, Speaker, Consultant, Advisor: MSD. M. Frueh: Financial Interests, Institutional, Advisory Board: BMS, AstraZeneca, MSD, Takeda, Roche, Lilly, Boehringer Ingelheim, Novartis, Amgen; Financial Interests, Institutional, Funding: BMS. K. Koster: Financial Interests, Institutional, Other, Travel support: Takeda, Janssen. S.I. Rothschild: Financial Interests, Institutional, Other, Honoraria: Roche, AstraZeneca, BMS, Boehringer Ingelheim, MSD, Novartis, Amgen, Lilly, Eisai, Merck. Pfizer, Takeda, Bayer, Janssen, Otsuka, PharmaMar, Sanofi; Financial Interests, Institutional, Advisory Board: AstraZeneca, Boehringer Ingelheim, BMS, Pfizer, Eisai, Lilly, Merck, MSD, Novartis, Roche, Takeda, Amgen, Otsuka, PharaMar; Financial Interests, Institutional, Other, Speakers Bureau: Roche, Sanofi/Aventis, Amgen, AstraZeneca, Takeda; Financial Interests, Institutional, Funding: AbbVie, BMS, AstraZeneca, Boehringer Ingelheim, Merck, Roche; Financial Interests, Institutional, Other, Travel support etc: Sanofi, Roche, BMS, MSD, AstraZeneca, Takeda, Boehringer Ingelheim, Amgen; Financial Interests, Personal, Other: Federal Drug Commission of the Federal Office of public Health; Financial Interests, Institutional, Other: SAKK. C. Britschgi: Financial Interests, Personal, Advisory Board: AstraZeneca, Pfizer, Roche, Takeda, Janssen, Boehringer Ingelheim, Roche, Merck, Sanofi; Financial Interests, Personal, Other, Travel support: AstraZeneca, Takeda, Amgen. M.T. Mark: Financial Interests, Institutional, Advisory Board: AstraZeneca, Merck, MSD, Sanofi, BMS, Roche, Takeda; Financial Interests, Personal, Other, Travel grants: Takeda, Sanofi, Roche; Financial Interests, Institutional, Funding: Gilead, Swiss Cancer Foundation. P.R. Froesch: Financial Interests, Institutional, Advisory Board: Roche, Takeda, Janssen, Pfizer, Novartis, Lilly, Sanofi. W. Janthur: Financial Interests, Personal, Advisory Board: Astra, Roche, Pfizer, BI, MSD, Takeda; Financial Interests, Personal, Other, Travel Grant: Astra, Roche. A.T. Allemann: Financial Interests, Institutional, Advisory Board: Janssen; Financial Interests, Personal, Other, Travel support: Janssen; Financial Interests, Institutional, Speaker, Consultant, Advisor: Janssen, AstraZeneca. F.W.F. Cerciello: Financial Interests, Institutional, Advisory Board: BMS, PharmaMar. L.A. Mauti: Financial Interests, Personal, Other, Honoraria: Takeda, Amgen, MSD, Astra; Financial Interests, Personal, Advisory Board: MSD, BMS, Astra, Merck, Roche, Pfizer, Novartis, Sanofi, Takeda; Financial Interests, Institutional, Funding: AstraZeneca; Financial Interests, Personal, Expert Testimony: MSD, Merck; Financial Interests, Personal, Other, Travel support: Roche, Sanofi, Takeda, Astra. All other authors have declared no conflicts of interest.
Resources from the same session
2237P - Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial
Presenter: Nicolas Huyghe
Session: Poster session 07
2238P - Tebentafusp reprograms immunosuppressive tumor-associated M2 macrophages towards anti-tumoral M1 macrophages
Presenter: Josep M. Piulats
Session: Poster session 07
2239P - Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types
Presenter: Elia Segui Solis
Session: Poster session 07
2240P - Novel genetic markers associated with immune checkpoint inhibitor induced immune-related adverse events
Presenter: Ik Shin Chin
Session: Poster session 07
2241P - A novel 89Zr-anti-PD-1 immuno-PET-CT may predict response to PD-1 inhibitors and improve response assessment in a lung cancer murine model receiving immunotherapy
Presenter: Ander Puyalto
Session: Poster session 07
2242P - Engineering immune-cell targeting nanoparticles for precise delivery of loaded-cargo and enhanced immunotherapy efficacy
Presenter: Na Kyeong Lee
Session: Poster session 07
2243P - Immune-modulating magnetic nanoparticles to enhance the immune response for the treatment of breast cancer metastasis and recurrence
Presenter: Jaesung Lim
Session: Poster session 07
2244P - Anti CTLA-4 and PD-1 monoclonal antibodies increases systemic SDF-1 and galectin-3 levels through NLRP3 and MyD-88 pathways in preclinical models
Presenter: Vincenzo Quagliariello
Session: Poster session 07
2245P - Graphene oxide: A promising platform for delivery of cancer immunotherapy
Presenter: Sorayut Chattrakarn
Session: Poster session 07
2246P - Tumor-infiltrating lymphocites and gene expression across multiple cancer-types: A translational analysis from the SOLTI-1904-ACROPOLI study
Presenter: Elia Segui Solis
Session: Poster session 07